Atea Pharmaceuticals, Inc. (AVIR)
Fuera de horario:
Atea Pharmaceuticals, Inc.
225 Franklin Street
Suite 2100
Boston, MA 02110
United States
857 284 8891
https://ateapharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 75
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Jean-Pierre Sommadossi Ph.D. | Founder, Chairman, CEO & President | 1.04M | N/D | 1956 |
| Ms. Andrea J. Corcoran J.D. | CFO, Executive VP of Legal & Secretary | 712.48k | N/D | 1962 |
| Dr. Janet M. J. Hammond M.D., Ph.D. | Chief Development Officer | 789.47k | N/D | 1960 |
| Dr. Maria Arantxa Horga M.D. | Chief Medical Officer | 679.58k | N/D | 1968 |
| Ms. Jonae R. Barnes | Senior Vice President of Investor Relations & Corporate Communications | N/D | N/D | N/D |
| Mr. Ariyapadi N. Krishnaraj | Vice President of Marketing | N/D | N/D | N/D |
| Mr. Adel Moussa Ph.D. | Executive Vice President of Chemistry | N/D | N/D | N/D |
| Mr. Xiao-Jian Zhou Ph.D. | Executive Vice President of Early Stage Development | N/D | N/D | N/D |
| Mr. John F. Vavricka | Chief Commercial Officer | 581.11k | N/D | 1963 |
| Mr. Keith Pietropaolo | Senior Vice President of Clinical Sciences | N/D | N/D | N/D |
Descripción
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Atea Pharmaceuticals, Inc. a partir del 1 de mayo de 2024 es 9. Las puntuaciones principales son Auditoría: 4; Junta: 10; Derechos del accionista: 8; Compensación: 9.
